Newamsterdam Pharma CO N.V. (NAMSW) — 8-K Filings

All 8-K filings from Newamsterdam Pharma CO N.V.. Browse 30 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (30)

NewAmsterdam Pharma Files 8-K — Sep 2, 2025 Risk: low
NewAmsterdam Pharma Co N.V. filed an 8-K on September 2, 2025, reporting on events related to Regulation FD disclosure and financial statements. The filing conf
NewAmsterdam Pharma Files 8-K — Aug 18, 2025 Risk: low
On August 18, 2025, NewAmsterdam Pharma Company N.V. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Fi
NewAmsterdam Pharma Enters Material Definitive Agreement — Aug 15, 2025 Risk: medium
On August 12, 2025, NewAmsterdam Pharma Company N.V. entered into a material definitive agreement. The filing also includes financial statements and exhibits re
NewAmsterdam Pharma Files 8-K on July 30, 2025 — Jul 30, 2025 Risk: low
NewAmsterdam Pharma Co N.V. filed an 8-K on July 30, 2025, reporting on various events. The filing includes information related to common stock and warrants, wi
NewAmsterdam Pharma Files 8-K on Officer/Director Changes — Jul 11, 2025 Risk: low
On July 11, 2025, NewAmsterdam Pharma Co N.V. filed an 8-K report detailing the departure of directors or certain officers, the election of directors, and the a
8-K Filing — Jun 11, 2025
NewAmsterdam Pharma Files 8-K — Jun 9, 2025 Risk: low
On June 9, 2025, NewAmsterdam Pharma Company N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events
NewAmsterdam Pharma Files 8-K on Shareholder Votes & Financials — Jun 6, 2025 Risk: low
NewAmsterdam Pharma Co N.V. filed an 8-K on June 6, 2025, reporting on matters submitted to a vote of security holders and financial statements as of June 4, 20
NewAmsterdam Pharma Files 8-K — May 7, 2025 Risk: low
NewAmsterdam Pharma Co N.V. filed an 8-K on May 7, 2025, reporting on other events and financial statements. The filing details their corporate structure and pr
NewAmsterdam Pharma Reports Director/Officer Changes — Apr 17, 2025 Risk: low
On April 15, 2025, NewAmsterdam Pharma Company N.V. filed an 8-K report detailing changes in its board of directors and officers, including the election of new
NewAmsterdam Pharma Files 8-K on Financials — Feb 26, 2025 Risk: low
NewAmsterdam Pharma Co N.V. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing includes financial sta
NewAmsterdam Pharma Files 8-K — Jan 10, 2025 Risk: low
On January 10, 2025, NewAmsterdam Pharma Company N.V. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and E
NewAmsterdam Pharma Enters Material Definitive Agreement — Dec 13, 2024 Risk: medium
On December 11, 2024, NewAmsterdam Pharma Company N.V. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and fina
NewAmsterdam Pharma Files 8-K — Dec 10, 2024 Risk: low
NewAmsterdam Pharma Company N.V. filed an 8-K on December 10, 2024, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits.
NewAmsterdam Pharma Files 8-K — Nov 20, 2024 Risk: low
On November 20, 2024, NewAmsterdam Pharma Co N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events
NewAmsterdam Pharma Files 8-K — Nov 18, 2024 Risk: low
NewAmsterdam Pharma Company N.V. filed an 8-K on November 18, 2024, reporting on various events. The filing includes information related to financial statements
NewAmsterdam Pharma Restates Financials — Oct 18, 2024 Risk: medium
NewAmsterdam Pharma Company N.V. announced on October 18, 2024, that it will not rely on previously issued financial statements or related audit reports. This d
NewAmsterdam Pharma Files 8-K — Aug 9, 2024 Risk: low
NewAmsterdam Pharma Co N.V. filed an 8-K on August 9, 2024, reporting other events and financial statements. The filing indicates the company's principal execut
NewAmsterdam Pharma Files 8-K — Jul 29, 2024 Risk: low
On July 29, 2024, NewAmsterdam Pharma Company N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events
NewAmsterdam Pharma Board Changes and Officer Compensation — Jul 18, 2024 Risk: medium
NewAmsterdam Pharma Company N.V. announced on July 16, 2024, a change in its board of directors. Specifically, Dr. Jane Osipov has been appointed as a new direc
NewAmsterdam Pharma Files 8-K Report — Jun 11, 2024 Risk: low
On June 11, 2024, NewAmsterdam Pharma Company N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events
NewAmsterdam Pharma Files 8-K on Shareholder Votes & Exhibits — Jun 7, 2024 Risk: low
On June 5, 2024, NewAmsterdam Pharma Company N.V. filed an 8-K report detailing the submission of matters to a vote of security holders, other events, and finan
NewAmsterdam Pharma Files 8-K on Financials — May 9, 2024 Risk: low
NewAmsterdam Pharma Company N.V. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing includes financial stat
NewAmsterdam Pharma Reports Board & Officer Changes — Apr 1, 2024 Risk: medium
On March 28, 2024, NewAmsterdam Pharma Co N.V. filed an 8-K report detailing changes in its board of directors and executive officers, including the appointment
NewAmsterdam Pharma Files 8-K — Mar 4, 2024 Risk: low
NewAmsterdam Pharma Co N.V. filed an 8-K on March 4, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing pertains to th
NewAmsterdam Pharma Files 8-K on Financial Condition — Feb 28, 2024 Risk: low
NewAmsterdam Pharma Company N.V. filed an 8-K on February 28, 2024, to report on its results of operations and financial condition. The filing indicates the com
NewAmsterdam Pharma Enters Material Definitive Agreement — Feb 15, 2024 Risk: medium
NewAmsterdam Pharma Company N.V. filed an 8-K on February 15, 2024, reporting an event that occurred on February 13, 2024. The filing indicates an "Entry into a
NewAmsterdam Pharma Confirms Public Trading Registration — Jan 22, 2024
NewAmsterdam Pharma Company N.V. filed an 8-K on January 22, 2024, primarily to disclose that its Ordinary Shares, with a nominal value of €0.12 per share, and
NewAmsterdam Pharma Reports Officer Comp, Director Changes — Jan 8, 2024
NewAmsterdam Pharma Company N.V. filed an 8-K on January 8, 2024, reporting an event that occurred on January 4, 2024. This filing indicates a change in compens
NewAmsterdam Pharma Confirms Nasdaq Listing for Shares & Warrants — Jan 4, 2024
NewAmsterdam Pharma Company N.V. filed an 8-K on January 4, 2024, to disclose that its Ordinary Shares, with a nominal value of €0.12 per share, are registered

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX